New Delhi: India’s exports of active pharmaceutical ingredients stood at approx. $41,500 crore in the last fiscal, which is higher than total imports $39,215 Crores.
Replying to a supplementary query during the Question Hour in the Rajya Sabha, the minister asserted that the Central government has taken several steps in the last 11 years to boost domestic production and reduce imports.
India’s imports amounted to Is $36,229 crore in 2022-23, $37,721 crore in 2023-24 and $39,214 crore in 2024-25.
The imports were from China $25,551 crore in 2022-23, $27,055 crore in 2023-24 and $29,064 crore in the last financial year.
China’s share increased to 74 percent in the last fiscal year from 70 percent in 2022-23, Nadda said.
However, the Minister stressed that I export more than I import.
“Export is $41,493 crore and the import we are doing is $39,215 Crores. So, it should be very clear that we are exporting more ACE than we are importing.”
The minister said that the center began a production-linked incentive program with expenditures of $6,940 Crores.
“The aim is to boost the manufacturing of key raw materials, pharmaceutical intermediaries and member states, and reduce dependence on imports from China,” he said.
The minister explained that anti-dumping duties and the minimum import price were set to maintain the market.
Nadda said that the Center is taking all steps to make India self-reliant in the pharmaceutical sector.
Under the PLI scheme to promote local manufacturing of critical KSMs/drug intermediates and active pharmaceutical ingredients in India, a local manufacturing capacity of around 56,800 tonnes per annum has been established for 28 out of the 41 critical products identified.
This scheme has resulted in cumulative sales of $2,720 crore reported till December 2025, including exports $527.96 crore, thus avoiding value of imports $2,192.04 crores. The program also created job opportunities for 4,896 people until December 2025.
This article was generated from an automated news feed without any modifications to the text.
